

## Exercise to preserve $\beta$ -cell function in recent-onset Type 1 diabetes mellitus (EXTOD) - a randomized controlled pilot trial

Narendran, Parth; Jackson, Nikki; Daley, Amanda; Thompson, Dylan; Stokes, Keith; Greenfield, Sheila; Charlton, Mary; Curran, Michelle; Solomon, Thomas; Nouwen, Arie; Lee, Siang I; Cooper, Ashley R ; Mostazir, Mohammod; Taylor, Rod S ; Kennedy, Amy; Andrews, Rob C

DOI:

[10.1111/dme.13439](https://doi.org/10.1111/dme.13439)

License:

Other (please specify with Rights Statement)

*Document Version*

Peer reviewed version

*Citation for published version (Harvard):*

Narendran, P, Jackson, N, Daley, A, Thompson, D, Stokes, K, Greenfield, S, Charlton, M, Curran, M, Solomon, T, Nouwen, A, Lee, SI, Cooper, AR, Mostazir, M, Taylor, RS, Kennedy, A & Andrews, RC 2017, 'Exercise to preserve  $\beta$ -cell function in recent-onset Type 1 diabetes mellitus (EXTOD) - a randomized controlled pilot trial', *Diabetic Medicine*, vol. 34, no. 11, pp. 1521-1531. <https://doi.org/10.1111/dme.13439>

[Link to publication on Research at Birmingham portal](#)

### **Publisher Rights Statement:**

Checked for eligibility: 21/09/2017

This is the peer reviewed version of the following article: Narendran P, Jackson N, Daley A, Thompson D, Stokes K, Greenfield S, Charlton M, Curran M, Solomon TP, Nouwen A, Lee SI. Exercise to preserve  $\beta$ -cell function in recent-onset Type 1 diabetes mellitus (EXTOD)—a randomized controlled pilot trial. *Diabetic Medicine*. 2017. which has been published in final form at [10.1111/dme.13439](https://doi.org/10.1111/dme.13439). This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.

### **General rights**

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

### **Take down policy**

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact [UBIRA@lists.bham.ac.uk](mailto:UBIRA@lists.bham.ac.uk) providing details and we will remove access to the work immediately and investigate.

**Supplementary Table 1 – Objectively measured activity and V02 max across the study**

6/12 month means are adjusted for their baseline scores. Within-group differences are paired t-tests from un-adjusted scores between two time points. Accelerometer counts were converted to MVPA using widely accepted thresholds as described in the manuscript text. Briefly, each 60-second epoch where counts exceeded 1951 was considered to be MVPA. VO<sub>2</sub> Max was assessed by two methods (Astrand-Ryhming and YMCA/ACSM) during a single Intervention test undertaken on a calibrated cycle ergometer and the mean of the two used. n is the number of outcomes at each time point.

	Mean (SD) Baseline	Mean (SE)		Mean Difference at Baseline (95% CI)	Mean Difference at 6 months (95% CI)	Mean Difference at 12 months (95% CI)
		6 months	12 months			
<b>Activity</b>						
<b>Total counts (n)</b>	<b>(49)</b>	<b>(33)</b>	<b>(30)</b>			
CONTROL	386 (154)	399 (36)	339 (36)			
INTERVENTION	357 (125)	398 (33)	400 (34)			
Within CONTROL					43 (-34 to 119)	-19 (-98 to 61)
Within INTERVENTION					41 (-29 to 111)	43 (-41 to 127)
INTERVENTION vs CONTROL				-29 (-108 to 51)	-2 (-102 to 99)	61 (-42 to 163)
<b>MVPA (min/week) (n)</b>	<b>(49)</b>	<b>(33)</b>	<b>(30)</b>			
CONTROL	277 (153)	279 (43)	235 (36)			
INTERVENTION	243 (141)	285 (40)	273 (34)			
Within CONTROL					28 (-49 to 106)	-12 (-93 to 69)
Within INTERVENTION					34 (-58 to 127)	18 (-69 to 106)
INTERVENTION vs CONTROL				-35 (-118 to 49)	6 (-114 to 126)	38 (-65 to 140)
<b>VO<sub>2</sub>max (ml/kg/min) (n)</b>	<b>(58)</b>	<b>(39)</b>	<b>(37)</b>			
CONTROL	35.14 (9.58)	33.85 (0.99)	33.69 (1.62)			
INTERVENTION	32.17 (5.61)	34.29 (0.96)	35.41 (1.19)			
Within CONTROL					-0.83 (-2.98 to 1.31)	-0.72 (-3.27 to 1.84)
Within INTERVENTION					0.43 (-1.69 to 2.66)	1.12 (-1.21 to 3.45)
INTERVENTION vs CONTROL				-2.97 (-7.12 to 1.18)	0.44 (-2.39 to 3.27)	1.72 (-1.67 to 5.2)